WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb. 15, 2006--Merck & Co., Inc. announced today that the New Drug Application (NDA) for JANUVIA(TM)* (sitagliptin phosphate) has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck expects FDA action on the NDA by mid-October. The Company also is moving forward as planned with filings in countries outside the United States.
